We are international

Sydney 2005: Single v Double HDT in MM: Second Analysis of the Trial GMMG-HD2
By Hartmut Goldschmidt, MD
Dr. Goldschmidt presented the second analysis of the GMMG-HD2 trial (the German Study). This trial is evaluating single versus double HDT followed by stem cell transplant (SCT) in newly diagnosed MM. Findings on 210 evaluable patients showed the median EFS in the single arm at 23 months versus 29 months in the double arm; no difference is seen in OS; however, a full analysis is not completed yet. He stated that Beta-2 microglobulin is a predictor of EFS in responsive patients.

Back to session summary

 related articles